Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Populations in Turkey
Funds research in Turkey on pneumococcal serotype distribution and antimicrobial resistance using advanced surveillance and diagnostics in pediatric and adult populations.
Funder: Pfizer Inc.
Due Dates: May 4, 2026 (Submission Deadline, full application — due by 23:59 EST)
Funding Amounts: Up to $120,000 USD per project; up to $180,000 USD if third-party lab services required; maximum project duration 3 years.
Summary: Supports research on pneumococcal disease serotype distribution and antimicrobial resistance in pediatric and adult populations in Turkey using advanced surveillance and diagnostic methods.
Description
This competitive grant supports research projects focused on the surveillance of pneumococcal disease serotype distribution among pediatric and adult populations in Turkey. Funded projects should investigate clinically confirmed pneumococcal infections, determine serotype-specific prevalence, analyze serotype distribution, and assess antimicrobial resistance patterns in pneumococcal isolates. Both active and passive surveillance methods are encouraged, leveraging data from hospital records, laboratory reports, and advanced diagnostic techniques such as PCR-based methods and genome sequencing. The grant aims to address evidence gaps in local epidemiology, provide robust epidemiological insights, and inform public health interventions. Preference is given to studies with clear plans for publishing results.
